{"id":"NCT01397786","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia","officialTitle":"A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2016-01","completion":"2016-01","firstPosted":"2011-07-20","resultsPosted":"2017-03-27","lastUpdate":"2017-05-10"},"enrollment":1044,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"OPC-34712","otherNames":[]}],"arms":[{"label":"OPC-34712","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs)","timeFrame":"From Baseline up to 52 Weeks","effectByArm":[{"arm":"Prior Brexpiprazole","deltaMin":60.2,"sd":null},{"arm":"Prior Placebo","deltaMin":56.4,"sd":null},{"arm":"De Novo","deltaMin":65.2,"sd":null},{"arm":"Total","deltaMin":60.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":148,"countries":["United States","Canada","Colombia","Croatia","Japan","Latvia","Malaysia","Mexico","Philippines","Poland","Puerto Rico","Romania","Russia","Serbia","Slovakia","South Korea","Taiwan","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["35235720","34901863","29985680","29415258","27188270"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":226},"commonTop":["Insomnia","Weight increased","Headache","Agitation","Akathisia"]}}